

FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET
NO: SO3078/4

APPLICATION NO.:
10/016,146

INVENTOR:
Cunningham, et. al.

Filed: 12/10/01

Group: 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,677,111	6/30/87	Haga, et. al.	514	274	10/1/85
	A2	5,256,812	10/26/93	Alig, et. al.	560	035	9/6/91
	A3	5,518,735	5/21/96	Sturzbecher, et. al.	424	449	11/15/91
	A4	5,753,230	5/19/98	Brooks	424	158.1	3/18/94
	A5	5,766,591	6/16/98	Brooks	424	184.1	12/30/94
	A6	6,013,651	1/11/00	Rogers	514	269	<i>duplicate</i>

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	B1	WO98/31359	7/23/98	WO				
	B2	WO98/14192	4/9/98	WO				
	B3	WO97/08145	03/06/97	WO				
	B4	AU-A-57984/94	10/6/94	Australia				
	B5	AU-A-79090/94	6/8/95	Australia				
	B6	2,059,857	7/25/92	Canada				
	B7	2,134,418	4/29/95	Canada				
	B8	0,343,893 A1	11/29/89	EPO				
	B9	0,343,894 A1	11/29/89	EPO				
	B10	0,478,328 A1	4/1/92	EPO				
	B11	0,478,363 A2	4/1/92	EPO				
	B12	DE 43 38 944 A1	5/18/95	Germany				
	B13	WO 93/08823	5/13/93	PCT				
	B14	WO 95/14714	6/1/95	PCT				
	B15	WO 95/28426	10/26/95	PCT				
	B16	WO 96/00574	1/11/96	PCT				
	B17	WO 96/00730	1/11/96	PCT				
	B18	94/0435	1/21/94	South Africa				
	B19	94/2124	3/25/94	South Africa				
	B20	94/9017	11/14/94	South Africa				
	B21	95/32710	12/7/95	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET
NO.: SO3078/4

APPLICATION NO.:
10/016,146

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

INVENTOR:
Cunningham, et. al.


(Use several sheets if necessary)

Filed: 12/10/01

Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	Carter, et. al., <i>Chemotherapy of Cancer</i> , Sec. Ed., John Wiley & Sons, NY, NY, (1981) 107-108
	C2	Pommier, et. al., <i>HIV-1 Integrase as Target for Antiviral Drugs</i> , Antiviral Chemistry & Chemotherapy, Vol. 8 (No. 6) (1997) 463-483
	C3	Nicklaus, et. al., <i>HIV-1 Integrase Pharmacophore: Discovery of Inhibitors Through Three-Dimensional Database Searching</i> , J. Med. Chem, 7 th ed., American Chemical Society, v. 40 (1997) 920-929
	C4	Hong, et. al., <i>Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching</i> , J. Med. Chem., American Chemical Society, v. 40, (1997) 930-936
	C5	Fields, <i>Integrins: Cell Adhesion Molecules in Cancer</i> , Exp. Opin. Ther. Patents, Ashley Publications Ltd., Vol. 8 (No. 6), (1998) 633-644
	C6	N.A., Derwent Abstract #00305 K/01
	C7	N.A., Derwent Abstract #57918 B/18
	C8	N.A., Derwent Abstract #77105 E/37
	C9	N.A., Derwent Abstract #87-009150/02
	C10	N.A., Derwent Abstract #87-065042/10
	C11	N.A. Derwent Abstract #89-055466/08
	C12	N.A. Derwent Abstract #89-349943/48
	C13	N.A. Derwent Abstract #92-398070/48
	C14	N.A. Derwent Abstract #93-060253/08
	C15	N.A. Derwent Abstract #93-08363/11
	C16	N.A. Derwent Abstract #93-127579/16
	C17	Adamis, <i>Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy</i> , American Journal of Ophthalmology, Vol 118 (1994) 445-450
	C18	Brooks, et. al., <i>Requirement for Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis</i> , Science, Vol 264 (1994) 569-571
	C19	Clyman, et. al., <i>β_1 and β_3 Integrins Have Different Roles in the Adhesion and Migration of Vascular Smooth Muscle Cells on Extracellular Matrix</i> , Experimental Cell Research, Vol 200, (1992)272-284
	C20	Liaw, et. al., <i>The Adhesive and Migratory Effects of Osteopontin Are Mediated Via Distinct Cell Surface Integrins : Role of $\alpha_v\beta_3$ in Smooth Muscle Migration to Osteopontin in Vitro</i> , Journal of Clinical Investigation, Vol. 95 (1995) 713-724
	C21	Peacock, et. al., <i>Angiogenesis Inhibition Suppresses Collagen Arthritis</i> , Journal of Experimental Medicine, Vol. 175 (1992) 1135-1138
	C22	Seftor, et. al., <i>Role of the $\alpha_v\beta_3$ Integrin in Human Melanoma Cell Invasion</i> , Proceedings of the National Academy of Sciences U.S.A., Vol. 89 (1992) 1557-1561
	C23	Schnur, et. al., <i>N-(5-Fluorobenzothiazol-2-yl)-2-guanidinothiazole-4-carboxamide. A Novel, Systemically Active Antitumor Agent Effective Against 3LL Lewis Lung Carcinoma</i> , Journal of Medicinal Chemistry, Vol. 34 (3) (1991) 914-918
	C24	Schnur, et. al., <i>Quantitative Structure-Activity Relationships of Antitumor Guanidinothiazolecarboxamides with Survival Enhancement for Therapy in the 3LL Lewis Lung Carcinoma Model</i> . Journal of Medicinal Chemistry, Vol. 34 (7) (1991) 1975-1982



FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICE

ATTY. DOCKET
NO.: SO3078/4

APPLICATION NO.:
10/016,146

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

INVENTOR:
Cunningham, et. al.

Filed: 12/10/01

Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C25	Smith, et. al., <i>Interactions of Integrins $\alpha_v\beta_3$ and GlycoProtein IIb-IIIa with Fibrinogen</i> , Journal of Medicinal Chemistry, Vol. 265 (21) (1990) 12267-12271
C26	White, <i>Integrins as Virus Receptors</i> , Current Biology, Vol 3 (9) (1993) 596-599 9
C27	Yue, <i>Osteopontin-Stimulated Vascular Smooth Muscle Cell Migration is Mediated by β_3 Integrin</i> , Experimental Cell Research, Vol. 214, (1994) 459-464
C28	Brooks, et. al., <i>Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels</i> , Cell, Vol. 79 (1994) 1157-1164
C29	Choi, et. al., <i>Inhibition of Neointimal Hyperplasia by Blocking $\alpha_v\beta_3$ Integrin with a Small Peptide Antagonist GpenGRDSPCA</i> , Journal of Vascular Surgery, Vol. 19 (1) 125-133

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

